U.S. markets closed
  • S&P 500

    3,647.29
    -7.75 (-0.21%)
     
  • Dow 30

    29,134.99
    -125.82 (-0.43%)
     
  • Nasdaq

    10,829.50
    +26.58 (+0.25%)
     
  • Russell 2000

    1,662.51
    +6.63 (+0.40%)
     
  • Crude Oil

    78.10
    -0.40 (-0.51%)
     
  • Gold

    1,637.40
    +1.20 (+0.07%)
     
  • Silver

    18.38
    +0.04 (+0.21%)
     
  • EUR/USD

    0.9599
    -0.0013 (-0.13%)
     
  • 10-Yr Bond

    3.9640
    +0.0860 (+2.22%)
     
  • GBP/USD

    1.0736
    +0.0053 (+0.50%)
     
  • USD/JPY

    144.7530
    +0.0730 (+0.05%)
     
  • BTC-USD

    18,981.16
    -121.92 (-0.64%)
     
  • CMC Crypto 200

    436.57
    -22.57 (-4.92%)
     
  • FTSE 100

    6,984.59
    -36.36 (-0.52%)
     
  • Nikkei 225

    26,571.87
    +140.32 (+0.53%)
     

Phoenix Biotech Acquisition Corp. (NASDAQ:PBAX) is favoured by institutional owners who hold 63% of the company

·4 min read

If you want to know who really controls Phoenix Biotech Acquisition Corp. (NASDAQ:PBAX), then you'll have to look at the makeup of its share registry. We can see that institutions own the lion's share in the company with 63% ownership. That is, the group stands to benefit the most if the stock rises (or lose the most if there is a downturn).

Given the vast amount of money and research capacities at their disposal, institutional ownership tends to carry a lot of weight, especially with individual investors. As a result, a sizeable amount of institutional money invested in a firm is generally viewed as a positive attribute.

In the chart below, we zoom in on the different ownership groups of Phoenix Biotech Acquisition.

View our latest analysis for Phoenix Biotech Acquisition

ownership-breakdown
ownership-breakdown

What Does The Institutional Ownership Tell Us About Phoenix Biotech Acquisition?

Institutions typically measure themselves against a benchmark when reporting to their own investors, so they often become more enthusiastic about a stock once it's included in a major index. We would expect most companies to have some institutions on the register, especially if they are growing.

As you can see, institutional investors have a fair amount of stake in Phoenix Biotech Acquisition. This implies the analysts working for those institutions have looked at the stock and they like it. But just like anyone else, they could be wrong. It is not uncommon to see a big share price drop if two large institutional investors try to sell out of a stock at the same time. So it is worth checking the past earnings trajectory of Phoenix Biotech Acquisition, (below). Of course, keep in mind that there are other factors to consider, too.

earnings-and-revenue-growth
earnings-and-revenue-growth

Investors should note that institutions actually own more than half the company, so they can collectively wield significant power. Hedge funds don't have many shares in Phoenix Biotech Acquisition. The company's CEO Christopher Ehrlich is the largest shareholder with 23% of shares outstanding. Meanwhile, the second and third largest shareholders, hold 4.9% and 4.5%, of the shares outstanding, respectively.

We did some more digging and found that 10 of the top shareholders account for roughly 51% of the register, implying that along with larger shareholders, there are a few smaller shareholders, thereby balancing out each others interests somewhat.

While it makes sense to study institutional ownership data for a company, it also makes sense to study analyst sentiments to know which way the wind is blowing. Our information suggests that there isn't any analyst coverage of the stock, so it is probably little known.

Insider Ownership Of Phoenix Biotech Acquisition

The definition of an insider can differ slightly between different countries, but members of the board of directors always count. The company management answer to the board and the latter should represent the interests of shareholders. Notably, sometimes top-level managers are on the board themselves.

Insider ownership is positive when it signals leadership are thinking like the true owners of the company. However, high insider ownership can also give immense power to a small group within the company. This can be negative in some circumstances.

Our information suggests that insiders maintain a significant holding in Phoenix Biotech Acquisition Corp.. Insiders have a US$53m stake in this US$232m business. This may suggest that the founders still own a lot of shares. You can click here to see if they have been buying or selling.

General Public Ownership

The general public, who are usually individual investors, hold a 14% stake in Phoenix Biotech Acquisition. While this group can't necessarily call the shots, it can certainly have a real influence on how the company is run.

Next Steps:

While it is well worth considering the different groups that own a company, there are other factors that are even more important. Consider for instance, the ever-present spectre of investment risk. We've identified 4 warning signs with Phoenix Biotech Acquisition (at least 2 which make us uncomfortable) , and understanding them should be part of your investment process.

Of course this may not be the best stock to buy. So take a peek at this free free list of interesting companies.

NB: Figures in this article are calculated using data from the last twelve months, which refer to the 12-month period ending on the last date of the month the financial statement is dated. This may not be consistent with full year annual report figures.

Have feedback on this article? Concerned about the content? Get in touch with us directly. Alternatively, email editorial-team (at) simplywallst.com.

This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.

Join A Paid User Research Session
You’ll receive a US$30 Amazon Gift card for 1 hour of your time while helping us build better investing tools for the individual investors like yourself. Sign up here